Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AMELIE

Financiado

Cerrado

Anchored Muscle cELls for IncontinencE

Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affected individuals and their families. Women with FI arising from childbirth injury may benefi... ver más

31/08/2025

UNIVERSITY COLLEGE...

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-06

SC1-BHC-07-2019: Regenerative medicine: from new ins...

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

UNIVERSITY COLLEGE LONDON

4.49M€ | Lider

CIRSA INTERACTIVE CORPORATIO...

276.18K€ | Participante

Universitätsklinikum Erlange...

114.84K€ | Participante

Proyectos interesantes

MUSIC

Medical Technol...

Data Science

7M€ Cerrado

TEC2017-83716-C2-2-R

Medical Technol...

Biotechnology

69K€ Cerrado

HISTOID

Medical Technol...

Biotechnology

1M€ Cerrado

PTQ-12-05665

Medical Technol...

Regenerative Me...

41K€ Cerrado

UroPrint

Medical Technol...

Biotechnology

3M€ Cerrado

OBSIDIAN

Medical Technol...

Biotechnology

3M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 63 meses Fecha Inicio: 2020-05-06
Fecha Fin: 2025-08-31

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affected individuals and their families. Women with FI arising from childbirth injury may benefit from regenerative medicine using autologous skeletal muscle derived cells (ASMDC) to restore function of damaged sphincter muscle. However, progress is hindered by sub-optimal manufacturing and delivery techniques contributing to inconsistent results. AMELIE proposes an innovative approach that uses ASMDC attached to implantable microcarriers that will enable delivery of a higher number of viable ASMDC into the damaged sphincter muscle, increasing the likelihood of cell engraftment, regeneration of muscle and improved continence. To achieve this, AMELIE will develop bespoke implantable microcarriers suitable for clinical use; establish robust bioprocessing for manufacture of the cell-microcarrier combination; and for the first time, robustly test, in a randomised clinical trial, the principle that delivery of ASMDC in an anchored, natural state, provides more effective and consistent treatment. AMELIE comprises a highly interdisciplinary, gender balanced, consortium of internationally recognised experts and key-opinion leaders with relevant experience from academia and industry across Europe in the fields of engineering (IST, PS, UCL, NHSBT), biological sciences (NHSBT, UCL, IISFJD), and translational regenerative medicine (QMUL, MUG, AUH, AU, RUH, UHE, IISFJD, CVBF). BCR will lead dissemination activity and stakeholder interaction with patients and the public, healthcare professionals, industry and third party FI charities across Europe to establish reciprocal dialogue with people that will interact with the new technology throughout the lifetime of the AMELIE project. TTOP will lead knowledge management and exploitation to develop a marketing strategy and business plan to facilitate future exploitation of the technology to ensure patient benefit.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores